39 pending office actions • 7 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Bristol-Myers Squibb Company | 24 |
| Mirati Therapeutics, Inc. | 8 |
| Mirati Therapeutics, Inc. | 2 |
| Bristol-Myers Squibb Company | 2 |
| Impact Biomedicines, Inc. | 1 |
| Bristol -Myers Squibb Company | 1 |
| Bristo-Myers Squibb Company | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18857946 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company | KRASNOW, NICHOLAS R | 1744 | Non-Final OA | Oct 18, 2024 |
| 18695032 | COMBINATIONS OF KRAS G12D INHIBITORS WITH IRINOTECAN AND RELATED METHODS OF TREATMENT | Mirati Therapeutics, Inc. | GONZALEZ, LUISALBERTO | 1624 | Non-Final OA | Mar 25, 2024 |
| 18591064 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | Impact Biomedicines, Inc. | SAEED, ALI S | 1616 | Final Rejection | Feb 29, 2024 |
| 18437950 | CRYSTALLINE FORMS OF 2-(4-(4-(AMINOMETHYL)-1-OXO-1,2-DIHYDROPHTHALAZIN-6-YL)-1-METHYL-1H-PYRAZOL-5-YL)-4-CHLORO-6-CYCLOPROPOXY-3-FLUOROBENZONITRILE | Mirati Therapeutics, Inc. | ROBINSON, MIKHAIL O'DONNEL | 1627 | Non-Final OA | Feb 09, 2024 |
| 18402803 | 2,3-DIHYDROBENZO[B][1,4]DIOXIN-6-YL CONTAINING COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company | HUTTER, GILLIAN A | 1625 | Non-Final OA | Jan 03, 2024 |
| 18389891 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company | KIM, SEONG JONG | 1621 | Non-Final OA | Dec 20, 2023 |
| 18389887 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company | INAM, SAHAR | 1622 | Non-Final OA | Dec 20, 2023 |
| 18572110 | Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | INAM, SAHAR | 1622 | Non-Final OA | Dec 19, 2023 |
| 18543421 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | JARRELL, NOBLE E | 1699 | Non-Final OA | Dec 18, 2023 |
| 18571051 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | HEASLEY, MEGHAN CHRISTINE | 1626 | Non-Final OA | Dec 15, 2023 |
| 18539519 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company | KIM, SEONG JONG | 1621 | Non-Final OA | Dec 14, 2023 |
| 18509844 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | Bristol-Myers Squibb Company | COFFA, SERGIO | 1658 | Non-Final OA | Nov 15, 2023 |
| 18560485 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company | KOSTURKO, GEORGE W | 1621 | Non-Final OA | Nov 13, 2023 |
| 18560520 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company | NEAGU, IRINA | 1629 | Non-Final OA | Nov 13, 2023 |
| 18504196 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company | AGGARWAL, SAHIL CHANDER | 1623 | Non-Final OA | Nov 08, 2023 |
| 18286961 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | SEITZ, ANTHONY JOSEPH | 1629 | Non-Final OA | Oct 13, 2023 |
| 18554675 | CYCLIC PEPTIDE IMMUNOMODULATORS | Bristol-Myers Squibb Company | HA, JULIE | 1654 | Non-Final OA | Oct 10, 2023 |
| 18551319 | IMMUNOMODULATORS | Bristol-Myers Squibb Company | BRADLEY, CHRISTINA | 1654 | Non-Final OA | Sep 19, 2023 |
| 18454489 | ANTI-ROR1 MACROCYCLIC PEPTIDES AND COMPOSITIONS | Bristol-Myers Squibb Company | KATAKAM, SUDHAKAR | 1658 | Non-Final OA | Aug 23, 2023 |
| 18274441 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | NOTTINGHAM, KYLE GREGORY | 1621 | Non-Final OA | Jul 26, 2023 |
| 18271579 | COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY | Bristol-Myers Squibb Company | DENT, ALANA HARRIS | 1643 | Non-Final OA | Jul 10, 2023 |
| 18247911 | AMINOIMIDAZOLE FPR2 AGONISTS | Bristol-Myers Squibb Company | WHITE, DAWANNA SHAR-DAY | 1627 | Non-Final OA | Apr 05, 2023 |
| 18026799 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | XIAO, YAN | 1642 | Non-Final OA | Mar 16, 2023 |
| 18180998 | PRODRUGGABLE ANTIBODIES, PRODRUGS THEREOF, AND METHODS OF USE AND MAKING | Bristol -Myers Squibb Company | CANELLA, KAREN A | 1643 | Non-Final OA | Mar 09, 2023 |
| 18173170 | INDOLE CARBOXAMIDE COMPOUNDS | Bristol-Myers Squibb Company | LADD, CAROLYN LOUISE | 1622 | Non-Final OA | Feb 23, 2023 |
| 18042018 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company | MOU, LIYUAN | 1628 | Non-Final OA | Feb 17, 2023 |
| 18018422 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | DAVIS, BRIAN J | 1614 | Final Rejection | Jan 27, 2023 |
| 18152056 | METHODS OF DIAGNOSING AND TREATING LUPUS | Bristol-Myers Squibb Company | STOICA, ELLY GERALD | 1647 | Non-Final OA | Jan 09, 2023 |
| 17998521 | DOSING AND ADMINISTRATION OF ACTIVATABLE ANTI-CTLA-4 ANTIBODY | Bristol-Myers Squibb Company | PETERS, ALEC JON | 1641 | Non-Final OA | Nov 11, 2022 |
| 17998137 | IMMUNOMODULATORS | Bristol-Myers Squibb Company | MIKNIS, ZACHARY J | 1658 | Non-Final OA | Nov 07, 2022 |
| 17905870 | ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY | Bristol-Myers Squibb Company | KAUFMAN, CLAIRE M | 1674 | Non-Final OA | Sep 08, 2022 |
| 17801733 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | VALLE, ERNESTO | 1623 | Final Rejection | Aug 23, 2022 |
| 17792905 | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company | MARTIN, KEVIN STEPHEN | 1624 | Non-Final OA | Jul 14, 2022 |
| 17786239 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company | SAMSELL, RILLA MARIE | 1624 | Final Rejection | Jun 16, 2022 |
| 17785585 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company | MAHLUM, JONATHAN DAVIS | 1625 | Non-Final OA | Jun 15, 2022 |
| 17785180 | BCR TRANSGENIC MICE WITH A COMMON LEADER SEQUENCE | Bristo-Myers Squibb Company | SINGH, ANOOP KUMAR | 1632 | Non-Final OA | Jun 14, 2022 |
| 17772343 | IMMUNOMODULATORS | Bristol-Myers Squibb Company | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | Non-Final OA | Apr 27, 2022 |
| 17760692 | DUAL CAPTURE METHOD FOR ANALYSIS OF ANTIBODY-DRUG CONJUGATES | Bristol-Myers Squibb Company | IVICH, FERNANDO NMN | 1678 | Final Rejection | Mar 15, 2022 |
| 17268130 | PROTEIN FRAGMENTATION CONTROL STRATEGY BY RE-OXIDATION IN DOWNSTREAM CHROMATOGRAPHY | Bristol-Myers Squibb Company | SPANGLER, JOSEPH RANKIN | 1656 | Non-Final OA | Feb 12, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial